Surface modification of pralidoxime chloride-loaded solid lipid nanoparticles for enhanced brain reactivation of organophosphorus-inhibited AChE: Pharmacokinetics in rat

Toxicology. 2020 Nov:444:152578. doi: 10.1016/j.tox.2020.152578. Epub 2020 Sep 6.

Abstract

The nanotechnological approach is an innovative strategy of high potential to achieve reactivation of organophosphorus-inhibited acetylcholinesterase in central nervous system. It was previously shown that pralidoxime chloride-loaded solid lipid nanoparticles (2-PAM-SLNs) are able to protect the brain against pesticide (paraoxon) central toxicity. In the present work, we increased brain AChE reactivation efficacy by PEGylation of 2-PAM-SLNs using PEG-lipid N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt) (DSPE-PEG2000) as a surface-modifier of SLNs. To perform pharmacokinetic study, a simple, sensitive (LLOQ 1.0 ng/mL) high-performance liquid chromatography tandem mass spectrometry with atmospheric pressure chemical ionization by multiple reaction monitoring mode (HPLC-APCI-MS) was developed. The method was compared to mass spectrometry with electrospray ionization. The method was validated for linearity, accuracy, precision, extraction recovery, matrix effect and stability. Acetophenone oxime was used as the internal standard for the quantification of 2-PAM in rat plasma and brain tissue after intravenous administration. 2-PAM-DSPE-PEG2000-SLNs of mean size about 80 nm (PDI = 0.26), zeta-potential of -55 mV and of high in vitro stability, prolonged the elimination phase of 2-PAM from the bloodstream more than 3 times compared to free 2-PAM. An increase in reactivation of POX-inhibited human brain acetylcholinesterase up to 36.08 ± 4.3 % after intravenous administration of 2-PAM-DSPE-PEG2000-SLNs (dose of 2-PAM is 5 mg/kg) was achieved. The result is one of the first examples where this level of brain acetylcholinesterase reactivation was achieved. Thus, the implementation of different approaches for targeting and modifying nanoparticles' surface gives hope for improving the antidotal treatment of organophosphorus poisoning by marketed reactivators.

Keywords: Acetylcholinesterase; Blood-brain barrier; HPLC; Organophosphorus agent; Oxime; Solid-lipid nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholinesterase / metabolism
  • Animals
  • Antidotes / administration & dosage*
  • Antidotes / chemistry
  • Antidotes / pharmacokinetics
  • Brain / drug effects
  • Brain / metabolism
  • Cholinesterase Inhibitors / toxicity*
  • Cholinesterase Reactivators / administration & dosage*
  • Cholinesterase Reactivators / blood
  • Cholinesterase Reactivators / chemistry
  • Cholinesterase Reactivators / pharmacokinetics
  • Drug Liberation
  • Female
  • Humans
  • Lipids / administration & dosage
  • Lipids / chemistry
  • Lipids / pharmacokinetics
  • Male
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Organophosphorus Compounds / toxicity
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / chemistry
  • Polyethylene Glycols / pharmacokinetics
  • Pralidoxime Compounds / administration & dosage*
  • Pralidoxime Compounds / blood
  • Pralidoxime Compounds / chemistry
  • Pralidoxime Compounds / pharmacokinetics
  • Rats, Wistar
  • Surface Properties

Substances

  • Antidotes
  • Cholinesterase Inhibitors
  • Cholinesterase Reactivators
  • Lipids
  • Organophosphorus Compounds
  • Pralidoxime Compounds
  • Polyethylene Glycols
  • Acetylcholinesterase
  • pralidoxime